Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Who’s winning in biotech’s tight market? - 6 days ago What 3 layoff stories reveal about pharma’s troubles - 13 days ago Is anyone taking the world’s priciest drugs? - 20 days ago What pharma has learned from AI - about 2 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 3 months ago Where competition is heating up in pharma - 4 months ago 3 big recent trial flops - 5 months ago The biggest questions hanging over pharma in 2024 - 8 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago 10 of our most read articles in 2023 - 9 months ago PharmaVoice 100s: Entrepreneurs - 11 months ago PharmaVoice 100s: Clinical trial gurus - 11 months ago 3 recent FDA adcomm rejections — and why they matter - 12 months ago The PharmaVoice 100: Standout execs - 12 months ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	3 FDA approval dates to watch in the year’s final push - 8 days ago Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision - 29 days ago Pharma execs react to final drug price negotiations with Medicare - about 1 month ago Read to lead: 6 books pharma execs swear by - about 2 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 2 months ago Behind Big Pharma’s layoffs — is there an end in sight? - 3 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 4 months ago 4 offbeat biotechs making a splash in the life sciences - 5 months ago 5 Big Pharma CEOs who saw major pay bumps in 2023 - 6 months ago These biotech hotspots are ripe for IPOs - 6 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 6 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 6 months ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - 7 months ago STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 9 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 9 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 9 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - 11 months ago
4	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - about 1 month ago The biotech news you missed this week - 2 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 4 months ago Lawmakers want to add more Chinese biotechs to defense list - 6 months ago
5	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	PBMs battle bipartisan scrutiny as lawmakers eye industry reform - about 2 months ago PBMs, PhRMA trade blame over drug costs in House hearing - about 1 year ago
6	Susanna Vogel Healthcare Dive Currently at Healthcare Dive. Seen in various outlets. Greenpoint healthcarejournalism	PBMs battle bipartisan scrutiny as lawmakers eye industry reform - about 2 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 3 months ago
8	Sydney Halleman Healthcare Dive Reporter/writer. Bad tweeter. Virginia, USA journalism	Latest 340B ruling delivers blow to providers - 4 months ago
9	Alexandra Pecci Pharma Voice Leading community for life sciences leaders. Washington, D.C. pharmaceuticalslife sciencescommunity building	How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues - 7 months ago 4 biotechs to watch in 2024 - 7 months ago 5 noteworthy pharma AI investments in 2023 - 9 months ago 4 historic FDA approvals from 2023 - 10 months ago The fortunes and flops of pharma M&A - 10 months ago Biopharma’s top 5 IPOs of 2023 (so far) - 10 months ago 5 of the best paid biopharma CEOs - 10 months ago In a record year for biotech bankruptcy, here are 3 companies that went under - 11 months ago Where have all the unicorns gone? A look at 4 billion-dollar biotechs - 12 months ago
10	Jonathan Gardner Healthcare Dive Senior reporter. BioPharma Dive. Charlottesville, Virginia BiopharmaceuticalsJournalism	Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts - 7 months ago Pharma benefited from basing business overseas. An international tax effort could spur a rethink. - 10 months ago

Journalists covering BioPharma, Legal, Pharma, Providers